| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer (NCT05168163) | Academic and Community Cancer Research United | 2022-05-27 |
| Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax (NCT05092373) | M.D. Anderson Cancer Center | 2022-04-29 |
| Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant (NCT05103904) | Emory University | 2022-04-19 |
| Durvalumab With/Without Tremelimumab After Palliative Hypofractionated Radiotherapy for Hepatocellular Carcinoma (NCT04430452) | Mary Feng, MD | 2022-02-04 |
| 68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer (NCT05176223) | Mayo Clinic | 2022-01-30 |
| Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (NCT04514484) | National Cancer Institute (NCI) | 2021-11-22 |
| Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer (NCT04605731) | City of Hope Medical Center | 2021-08-03 |
| Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events (NCT05038254) | M.D. Anderson Cancer Center | 2021-05-12 |
| Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer (NCT04380545) | M.D. Anderson Cancer Center | 2021-01-13 |
| Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers (NCT04221893) | University of California, San Francisco | 2020-08-07 |
| Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver (NCT04175912) | National Cancer Institute (NCI) | 2020-03-16 |
| Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) (NCT03896646) | M.D. Anderson Cancer Center | 2019-10-10 |
| Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer (NCT03942328) | Mayo Clinic | 2019-09-19 |
| An Investigational Scan (Magnetic Resonance Elastography) in Detecting Treatment Response in Patients With Advanced Liver Cancer (NCT04022746) | M.D. Anderson Cancer Center | 2019-06-11 |
| Intravital Microscopy in Human Solid Tumors (NCT03823144) | Mayo Clinic | 2019-02-28 |
| IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer (NCT03655002) | City of Hope Medical Center | 2019-02-21 |
| BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer (NCT03695250) | Edward Kim | 2018-10-16 |
| Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer (NCT03439891) | Robin Kate Kelley | 2018-04-16 |
| Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma (NCT01176604) | M.D. Anderson Cancer Center | 2010-08-04 |